John C. Reed

From Wikipedia, the free encyclopedia

John C. Reed (born October 11, 1958) is executive vice president of pharmaceutical research and development at Johnson & Johnson. He was previously the executive vice president and global head of research and development of Sanofi, the global head of pharmaceutical research and early development at Roche, and the chief executive of the Sanford-Burnham Medical Research Institute in La Jolla, San Diego, California.[1][2] He was a pioneer in the field of apoptosis particularly with regard to cancer; he was studying oncogenes and discovered that some of them appeared to regulate cell death rather than cell division.[3][4]

Research[edit]

Reed earned his B.A. at the University of Virginia and his M.D. Ph.D. at University of Pennsylvania School of Medicine. He then did his postdoctoral fellowship at the Wistar Institute of Anatomy and Biology. He is a fellow of the American Association for the Advancement of Science.

References[edit]

  1. ^ "John Reed lands in the top R&D post at J&J in his latest Big Pharma debut". Endpoints News.
  2. ^ "Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D | Johnson & Johnson". Content Lab U.S.
  3. ^ "The Burnham Institute's John C. Reed on the Birth of Cell-Death Research".
  4. ^ Pollack, Andrew (15 January 2013). "Roche Hires Academic to Take Lead on Research". The New York Times.